Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	17,052	16,583	11,592	14,105	11,381
Short-Term Investments	-	-	57.81	90.67	57.33	93.4
Cash & Short-Term Investments	17,052	17,052	16,641	11,683	14,163	11,474
Cash Growth	2.76%	2.48%	42.44%	-17.51%	23.43%	2.59%
Accounts Receivable	-	33,419	18,584	36,652	31,011	25,721
Other Receivables	-	-	8,225	5,743	5,576	4,797
Receivables	-	33,419	26,809	42,394	36,588	30,517
Inventory	-	30,285	25,131	23,736	24,998	22,768
Prepaid Expenses	-	-	266.9	2,275	2,199	2,198
Other Current Assets	-	12,198	5,434	27,167	4,876	6,638
Total Current Assets	-	92,955	74,281	107,255	82,823	73,596
Property, Plant & Equipment	-	38,614	35,375	41,951	46,117	41,756
Long-Term Investments	-	563.55	7,958	472.77	556.64	518.95
Goodwill	-	702.66	673.59	736.19	600.19	580.11
Other Intangible Assets	-	13,900	12,672	23,427	22,254	22,769
Long-Term Deferred Tax Assets	-	11,241	10,497	18,059	16,861	15,347
Other Long-Term Assets	-	2,520	2,130	1,816	1,620	1,469
Total Assets	-	160,496	143,586	193,717	170,833	156,036
Accounts Payable	-	25,795	25,359	20,004	22,887	22,378
Accrued Expenses	-	-	12,473	14,427	7,168	6,346
Short-Term Debt	-	16,815	8,334	3,500	3,700	5,130
Current Portion of Long-Term Debt	-	-	1,572	1,456	7,286	2,856
Current Portion of Leases	-	922.62	886.43	830.39	916.78	742.54
Current Income Taxes Payable	-	283.74	2,910	984.98	931.2	501.2
Other Current Liabilities	-	15,854	6,652	9,848	4,005	4,057
Total Current Liabilities	-	59,670	58,186	51,051	46,894	42,010
Long-Term Debt	-	5,127	-	38,521	25,717	38,888
Long-Term Leases	-	1,862	1,517	1,771	2,000	2,240
Long-Term Deferred Tax Liabilities	-	585.88	2.8	5.14	314.95	287.49
Other Long-Term Liabilities	-	4,760	5,405	3,976	1,525	1,967
Total Liabilities	-	72,005	65,111	95,324	76,452	85,393
Common Stock	-	282.19	282.19	282.17	282.17	282.17
Additional Paid-In Capital	-	-	16,866	16,854	16,854	16,854
Retained Earnings	-	-	80,160	96,026	93,564	73,791
Comprehensive Income & Other	-	88,212	-18,828	-18,422	-19,834	-20,281
Total Common Equity	88,494	88,494	78,479	94,739	90,866	70,646
Minority Interest	-	-3.71	-3.8	3,653	3,515	-3.54
Shareholders' Equity	88,491	88,491	78,475	98,393	94,381	70,643
Total Liabilities & Equity	-	160,496	143,586	193,717	170,833	156,036
Total Debt	24,727	24,727	12,309	46,079	39,620	49,857
Net Cash (Debt)	-7,674	-7,674	4,331	-34,396	-25,458	-38,383
Net Cash Per Share	-27.19	-27.19	15.35	-121.90	-90.22	-136.03
Filing Date Shares Outstanding	282.36	290.63	282.19	282.17	282.17	282.17
Total Common Shares Outstanding	282.36	290.63	282.19	282.17	282.17	282.17
Working Capital	-	33,284	16,095	56,205	35,929	31,586
Book Value Per Share	313.63	304.50	278.11	335.75	322.03	250.37
Tangible Book Value	73,891	73,891	65,134	70,576	68,012	47,297
Tangible Book Value Per Share	261.88	254.25	230.82	250.12	241.04	167.62
Land	-	-	461.25	423.45	688.97	581.31
Buildings	-	-	17,556	16,069	17,211	13,053
Machinery	-	-	32,155	32,052	34,167	28,352
Construction In Progress	-	-	4,193	10,658	9,211	12,178

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.